Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

2203 Pages (Click to Jump) V  < 1 2 3 4 5 > »    
 
  
Reply to this topic

CST, CELLESTIS LIMITED
henrietta
post Posted: Feb 4 2013, 06:50 PM
  Quote Post


Posts: 4,517
Thanks: 740


In Reply To: macduffy's post @ Feb 4 2013, 05:47 PM

Interesting .......... I would have expected quite a lot higher sales, given the size of company and resources. I think our Aussie doctors did pretty well on their own, and obviously almost wore themselves out in the process.
Crying shame CST was sold.
CheersJ





--------------------
"Sometimes I sits and thinks, and sometimes I just sits." Satchel Paige

"No road is long with good company." Traditional

Said 'Thanks' for this post: mrcurly  
 
macduffy
post Posted: Feb 4 2013, 05:47 PM
  Quote Post


Posts: 2,379
Thanks: 263


http://www.bloomberg.com/news/2013-02-03/s...ning-sales.html



No comment needed!


sadsmiley02.gif


Said 'Thanks' for this post: Squiggs  
 
mrcurly
post Posted: Feb 2 2013, 03:46 PM
  Quote Post


Posts: 93
Thanks: 45


In Reply To: mulgoaman's post @ Feb 2 2013, 01:59 PM

Thanks Ciabatta and Mulgoaman,

Great (?) minds must think alike:
- I am heavily into SYR, and CSE which is the cheap entry to SYR. The electric car battery usage for graphite is one that I see ramping up hugely in coming years. The new Chinese SAAB owner and some other car manufacturers are betting big on China needing electric vehicles to reduce pollution and reliance on oil. This should underpin increased demand for the Balama end product...
- Was in Optiscan for a few years and attended AGM's for a while, but pulled out when I saw more research than commercialisation happening. Haven't followed it for a few years but didn't Pentax licence the technology, buy the Optiscan parts or something like that? I used to work in Japan for a large optics/electronics company and have seen how they treat sub-contractors so suspect there has been pressure to keep prices down and make product modifications.
- Will look at Chalice... Thanks for the tip :-)

Cheers,

Curly

 
mulgoaman
post Posted: Feb 2 2013, 01:59 PM
  Quote Post


Posts: 346
Thanks: 267


In Reply To: mrcurly's post @ Feb 1 2013, 12:38 PM

Hello mrcurly,

Yes, I guess there were positives to come from the CST takeover - I did park most of my CST sale proceeds into Term Deposit and have now started to look elsewhere while interest rates are in decline.

I have taken an interest recently in a small mining company - Chalice Gold Mines. They have a prospect in Eritrea, which shows much early promise. It is near the "world class" Bisha Mine owned by Canada's Nevsun Resources (can be googled if you need to know more). Chalice currently is trading at 19c. which gives it a market cap. of $48m., which happens to be covered by their cash reserves ($53m. at 31/12/12). Chairman Tim Goyder (a cousin of Westfarmers Richard), is, from what you read, an acknowledged deal maker and over the time I've been watching the stock has increased his holding in the company - must be a good sign. Chalice are based in W.A. which for me is, unfortunately, a long way to go if you wish to attend an A.G.M. and attempt to assess the quality of the people at the top table.

On the disappointment page of the ledger sits Optiscan. They still claim to be world leaders with their "high quality minimally invasive microscopy, enabling earlier, more accurate and efficient cancer diagnosis and treatment" amongst other things. (It's all there in their A.G.M. slide presentation via A.S.X. announcements (20/11/12). Market cap. is $18m. From many years ago, Cellestis poster Skorpian used to make constructive posts on the Optiscan site but interest from all posters has waned over the years. It all seemed very promising - I don't know if management is on the ball sufficiently to deliver the goods or not. I still hold modestly, and hope.

Regards,

MM

 
ciabatta
post Posted: Feb 1 2013, 09:01 PM
  Quote Post


Posts: 424
Thanks: 183


In Reply To: mulgoaman's post @ Feb 1 2013, 09:49 AM

Hi Mr Curly,

Some interesting parallels with a small Melbourne-based company, with roughly half the shares still owned by the original four who set things up, and who have now proven that the tenements they hold in distant Mozambique contain, by far, the largest graphite deposits in the world, and. in the same orebody, the largest vanadium deposit in the world.

The company is Syrah Resources (SYR), and, at a current MC of around $400m ($3.20 per share), is well worth a look. They expect to be a significant producer before the end of 2014. Could well be taken over, a la CST, but appear to have the resources to evolve into a major independent miner. I hope so!

Cheers, Ciabatta

 
mrcurly
post Posted: Feb 1 2013, 12:38 PM
  Quote Post


Posts: 93
Thanks: 45


In Reply To: mulgoaman's post @ Feb 1 2013, 09:49 AM

Hi Mulgoaman,
Yes, the Cellestis fundamental story continues on and the acquirer now gets the long term benefits.
On the positive side:
- We received cash at a time that the whole market went down or sideways, even good stocks with great stories
- The R&D for this stays in Australia as far as I know
- The two Doctors are probably happier working as part of a bigger machine again, without the hassle of running a listed company. When those two gentlemen decided they didn't want to stay on the listed company train then it was time for everyone to get off

Any shares you follow now that have similar characteristics to CST? i.e. Strong fundamental story, good driven and honest management, well priced?
Independence Group (IGO) is the closest to this in the stocks I follow closely, albeit in the materials sector and subject to the winds of commodity prices.

Cheers,

Curly


 


mulgoaman
post Posted: Feb 1 2013, 09:49 AM
  Quote Post


Posts: 346
Thanks: 267


In Reply To: mrcurly's post @ Oct 22 2012, 12:55 PM

Hello mrcurly, I now see where Qiagen have reported its full year (2012) results. They say in part:

"the Quantiferon TB test (acquired with Cellestis in 2011) achieved more than 20% CER pro forma growth in 2012 on initiatives in the US and Europe to drive greater use of this new 'gold standard' test for latent tuberculosis (TB)"

I did need to look into the CER bit - apparently it means "Constant Exchange Rates" by restating the prior years figures using the exchange rates that were in force in the current reporting year. This is to strip out the effect of changing currency rates and show comparatives on a like for like basis.

A 20% growth on our previous investment in Cellestis wouldn't have been hard to take either. But as most posters here have commented
- time to get over it.

Regards,

MM

 
grizzly1
post Posted: Oct 23 2012, 01:31 PM
  Quote Post


Posts: 37
Thanks: 109


In Reply To: mrcurly's post @ Oct 22 2012, 12:55 PM

I'm still working in routine diagnostic pathology laboraties and I can attest that a recent case of TB at one of our hospitals resulted in the screening of contacts/staff by Quantiferon, inexorable & inevitable are two words that come to mind as I see this test take over.

reading this post below with the 7% from CST as opposed to 6% for the rest of their portfolio just confirms what I see each day at work.

 
mrcurly
post Posted: Oct 22 2012, 12:55 PM
  Quote Post


Posts: 93
Thanks: 45


In Reply To: mulgoaman's post @ Sep 3 2012, 09:31 PM

From Qiagens latest quarterly report:

We are also pleased with the successful integration of the 2011 acquisitions of Cellestis and Ipsogen, which showed strong growth as part of QIAGEN in the first quarter of 2012.

and

Net sales grew at a double-digit pace across all geographic regions, and supported by contributions from all customer classes. At constant exchange rates, net sales rose 13%, with the Cellestis (as of August 29, 2011) and Ipsogen (as of July 12, 2011) acquisitions providing seven percentage points and the rest of the QIAGEN product portfolio contributing six percentage points. Currency movements had a negative net impact of one percentage point on reported sales growth.

and

The QuantiFERON-TB Gold test for detection of latent tuberculosis, added to the QIAGEN portfolio in August 2011 through the acquisition of Cellestis, provided dynamic growth contributions.

and

QIAGEN reaffirms its goal to accelerate sales and adjusted earnings growth in 2012 compared to 2011. For the full year, total net sales are expected to rise approximately 6-8% CER on a mix of organic contributions as well as the Cellestis and Ipsogen acquisitions completed in 2011.


Sounds like the sales have continued to progress well even through tough economic times. They should be very happy with their purchase... Not sure if the CST share price would have been any better than the T/O price if they were still independent, as the markets have been unenthusiastic about most things, but it sounds like things are still going to plan.


Said 'Thanks' for this post: mulgoaman  hogie  
 
mulgoaman
post Posted: Sep 3 2012, 09:31 PM
  Quote Post


Posts: 346
Thanks: 267


In Reply To: henrietta's post @ Aug 29 2012, 08:30 AM

Hello J.,

Still hurting ? Don't know if hurting is the right description - probably cheesed off is a bit closer. But what's in a word or two.

And probably one of my main gripes is that having been a shareholder for those many years, and in particular the full 2010-11 period, is that when settlement of the S.O.A. was made CST was then "removed from the official list following confirmation of the implementation of the scheme" The following day (31st August) would have been the deadline for companies to report their annual results to the ASX. It always seemed convenient to me that management did not to have to report to shareholders. This was achieved by tidying things up by just the odd day (30th August). I know it would have been only academic for us shareholders but nevertheless interesting to know how the year transpired and we could have merrily used those figures in our hypothetical calculations in assessing the worth of the company.

My CST posts were mainly covering what I gleaned by going to AGMs and briefing sessions plus also where I attempted to point out that management weren't very shareholder friendly in carrying out their duties for the bulk of shareholders. Unfortunately I think I was pretty close to the mark with those observations. Having held shares in Blackmores and PanAust (to name a couple) over the years and attended their AGMs I think the ASX could lift the bar in what shareholders should received from their managements and not let companies, such as CST get away with the bare minimum of communications.

Here endeth the cheesed off session.

Regards,

MM

 
 


2203 Pages (Click to Jump) V  < 1 2 3 4 5 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING